TABLE 4.

Comparison of pharmacokinetic parameter estimates for GZDV between treatment regimens

Treatment or treatment comparison	AUC0–∞ (μg · h/ml)				Cmax (μg/ml)				Tmax (h)a				t1/2 (h)
	Geometric LSMb	95% CI	LSM ratioc	90% CI	Geometric LSMb	95% CI	LSM ratioc	90% CI	Median	Range	Median difference	90% CI	Geometric meanb	95% CI	LSM ratioc	90% CI
Treatment
GZDV	11.8	10.2–13.7			9.11	7.46–11.1			0.75	0.50–1.00			1.38	1.23–1.54
Abacavir + ZDV	16.5	14.2–19.1			8.57	7.02–10.5			1.50	0.75–2.02			1.28	1.15–1.44
ZDV + 3TC	11.7	10.1–13.6			8.79	7.19–10.7			0.75	0.50–1.50			1.38	1.23–1.54
Abacavir + ZDV + 3TC	15.6	13.4–18.1			8.15	6.67–9.95			1.00	0.75–2.00			1.24	1.11–1.39
Treatment comparison
Abacavir + ZDV vs ZDV			1.40	1.30–1.50			0.94	0.81–1.09			0.62	0.38–0.87			0.93	0.88–0.99
ZDV + 3TC vs ZDV			0.99	0.93–1.06			0.97	0.83–1.12			0.13	0.00–0.25			1.00	0.94–1.06
Abacavir + ZDV + 3TC vs ZDV			1.32	1.24–1.42			0.90	0.77–1.04			0.50	0.25–0.75			0.90	0.85–0.96

^aUntransformed data. 

^bValues for geometric LSMs for all pharmacokinetic parameters are given with the 95% CIs. 

^cValues are ratios of geometric LSM for test treatment to geometric LSM for reference treatment.